4-[3-(6-Phenoxy-pyridin-3-yl)-propionyl]-piperazin-2-one | 1036223-88-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[3-(6-Phenoxy-pyridin-3-yl)-propionyl]-piperazin-2-one
• 英文别名: 4-[3-(6-phenoxypyridin-3-yl)propanoyl]piperazin-2-one
• CAS: 1036223-88-7
• 化学式: C₁₈H₁₉N₃O₃
• 分子量: 325.367
• InChiKey: VZERJJDCCYIOCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-[3-(6-phenoxy-pyridin-3-yl)-acryloyl]-piperazin-2-one 在 钯 乙腈 、 水 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、13.51 MPa 条件下， 反应 12.0h， 生成 4-[3-(6-Phenoxy-pyridin-3-yl)-propionyl]-piperazin-2-one
  参考文献：
  名称：

  Heteroaryl-substituted carboxamides and their use as pharmaceuticals

  摘要：

  本发明涉及式I的杂环取代羧酰胺，其中Het，A，X，R1，R2和R3具有所述索权要求中指示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体而言，式I的化合物上调内皮型NO合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况下。本发明还涉及制备式I的化合物的方法，包括它们的制药组合物以及使用式I的化合物制造用于刺激内皮型NO合酶表达或治疗各种疾病的药物，包括心血管疾病如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心脏功能不全等。

  公开号：

  US08188291B2

文献信息

• Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
  申请人：sanofi-aventis

  公开号：EP1939181A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环取代羧酰胺，其中Het、A、X、R1、R2和R3具有索引中指示的含义，这些化合物调节内皮一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮一氧化氮合酶酶的表达，并可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况。该发明还涉及公式I化合物的制备方法，包括它们的药物组合物，以及公式I化合物用于制造刺激内皮一氧化氮合酶表达或治疗各种疾病的药物的用途，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20100016337A1

  公开（公告）日：2010-01-21

  The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环取代羧酰胺，其中Het、A、X、R1、R2和R3在权利要求中所示，它们调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体来说，公式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的制药组成物，以及公式I化合物用于制造用于刺激内皮型NO合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心力衰竭等。
• HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE
  申请人：Sanofi-Aventis

  公开号：EP2097382A1

  公开（公告）日：2009-09-09
• US8188291B2
  申请人：——

  公开号：US8188291B2

  公开（公告）日：2012-05-29
• [EN] HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE<br/>[FR] CARBOXAMIDES SUBSTITUÉS PAR DES HÉTÉROARYLES ET LEUR UTILISATION DANS LA STIMULATION DE L'EXPRESSION DE LA NO SYNTHASE
  申请人：SANOFI AVENTIS

  公开号：WO2008077507A1

  公开（公告）日：2008-07-03

  [EN] The present invention relates to heteroaryl-substituted carboxamides of the formula (I) in which Het, A, X, R¹, R² and R³ have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula (I) upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula (I), to pharmaceutical compositions comprising them, and to the use of compounds of the formula (I) for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
  [FR] La présente invention concerne des carboxamides substitués par des hétéroaryles de formule (I), Het, A, X, R¹, R² et R³ ayant les significations indiquées dans les revendications, qui modulent la transcription de l'oxyde nitrique (NO) synthase endothéliale et sont des composés ayant de la valeur comme composés actifs pharmacologiquement. Spécifiquement, les composés de formule (I) régulent vers le haut l'expression de l'enzyme NO synthase endothéliale et peuvent être appliqués dans des conditions où l'on souhaite l'expression augmentée de ladite enzyme ou un niveau de NO augmenté ou la normalisation d'un niveau de NO diminué. L'invention concerne de plus des procédés de préparation des composés de formule (I), des compositions pharmaceutiques les comprenant, et l'utilisation de composés de formule (I) dans la fabrication d'un médicament pour la stimulation de l'expression de la NO synthase endothéliale ou pour le traitement de diverses maladies comprenant des troubles cardiovasculaires tels que l'athérosclérose, la thrombose, une maladie coronarienne, l'hypertension et l'insuffisance cardiaque, par exemple.